Rigel Pharmaceuticals RIGL

NAS: RIGL | ISIN: US7665596034   4/06/2025
20,54 USD (+0,74%)
(+0,74%)   4/06/2025

6 mei 2025 · Rigel Reports First Quarter 2025 Financial Results and Provides Business Update · Persbericht

29 april 2025 · Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update · Persbericht

4 april 2025 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

27 maart 2025 · Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation · Persbericht

10 maart 2025 · Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors · Persbericht

4 maart 2025 · Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update · Persbericht

12 september 2024 · Rigel to Present at the 2024 Cantor Global Healthcare Conference · Persbericht

5 september 2024 · Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML · Persbericht

3 september 2024 · Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan · Persbericht

29 augustus 2024 · Rigel to Participate in Upcoming September Investor Conferences · Persbericht

6 augustus 2024 · Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

30 juli 2024 · Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update · Persbericht

12 juli 2024 · Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

25 juni 2024 · Rigel Announces Reverse Stock Split · Persbericht

24 juni 2024 · Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application · Persbericht

14 juni 2024 · Rigel Announces Five Presentations at the EHA2024 Hybrid Congress · Persbericht

3 juni 2024 · Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting · Persbericht

30 mei 2024 · Rigel to Present at the Jefferies Global Healthcare Conference · Persbericht

23 mei 2024 · Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress · Persbericht

7 mei 2024 · Rigel Reports First Quarter 2024 Financial Results and Provides Business Update · Persbericht

Mijn selecties